Arrowhead: RNAi Pipeline Gains Momentum – Plozasiran on the Verge of Next Growth Surge
Reading Time: 3 minutes
Arrowhead Pharmaceuticals develops drugs based on RNA interference (RNAi) to selectively silence disease-causing genes. The company's proprietary TRiM platform serves as the foundation for therapeutics aimed at rare diseases. The EU market approval in July 2026 for Redemplo (Plozasiran) for the treatment of familial chylomicronemia syndrome (FCS) drives its international expansion. Positive Phase 3 study data for Plozasiran in severe hypertriglyceridemia (sHTG) and an FDA Priority Review Voucher in August further support the stock price. ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
